Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Phase II Study of Transperineal Intraprostatic Injection of PRX302 for the Treatment of Benign Prostatic Hyperplasia

NCT00889707 is registered in ClinicalTrials.gov with Sophiris Bio Corp as lead sponsor.

NCT NCT00889707
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00889707 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Phase II Study of Transperineal Intraprostatic Injection of PRX302 for the Treatment of Benign Prostatic Hyperplasia
Lead sponsor
Sophiris Bio Corp
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2009
Completion date
September 30, 2010
Enrollment
92 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

benign prostatic hyperplasia